D3 Drug Discovery and Development

D3 Bio is a clinical-stage biotechnology company focused on the discovery and development of precision oncology and immunology therapies. Founded in 2020 and headquartered in Shanghai, the company employs a unique "Development leading to Discovery" approach, utilizing clinical insights and biomarker strategies to guide laboratory research. Its lead candidate, elisrasib (D3S-001), is a next-generation KRAS G12C inhibitor currently in Phase 2 trials for various solid tumors, including non-small cell lung cancer and colorectal cancer. D3 Bio is backed by a syndicate of world-class investors, including Temasek, Medicxi, and Sequoia China, and aims to transform life-threatening cancers into manageable chronic conditions.